Transcriptional Dysregulation in Neurodegeneration

Transcriptional Dysregulation in Neurodegeneration

Introduction

Transcriptional Dysregulation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Pathway Diagram: Transcriptional Dysregulation Mechanisms

Transcriptional Dysregulation in Neurodegeneration

Introduction

Transcriptional Dysregulation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Pathway Diagram: Transcriptional Dysregulation Mechanisms

Transcriptional dysregulation is a central pathological feature of neurodegenerative diseases, including [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), [huntington-pathway](/mechanisms/huntington-pathway), and [ftd](/diseases/frontotemporal-dementia). The precise regulation of gene expression [@lu2014] is essential for neuronal survival, synaptic plasticity, and brain homeostasis, and its disruption contributes directly to neuronal dysfunction and death. Transcriptional dysregulation encompasses aberrant activity of transcription factors, [epigenetic [@mathys2019] modifications], chromatin [@refa] remodeling defects, RNA processing errors, and epitranscriptomic alterations that collectively derail the gene expression programs required to maintain neuronal identity and function ([Berson et al., 2018))](https://pmc.ncbi.nlm.nih.gov/articles/PMC3854070/)) ([Berson et al., 2018](https://pmc.ncbi.nlm.nih.gov/articles/PMC3854070/)). [@mathys2019]

Emerging evidence from single-cell RNA sequencing, ATAC-seq, and epigenomic profiling has revealed that transcriptional changes in neurodegeneration are cell-type-specific, with distinct signatures in excitatory [neurons](/entities/neurons), inhibitory [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia) ([Zuccato et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12878693/)). [@lu2014]

Transcription Factor Dysregulation

REST [@ref]/NRSF

The RE1-silencing transcription factor (REST), also known as neuron-restrictive silencer factor (NRSF), plays a critical neuroprotective role in aging and neurodegeneration. In healthy aging brains, REST is upregulated in [neurons](/entities/neurons) and represses genes that promote cell death, oxidative stress, and [amyloid-beta](/proteins/amyloid-beta) ([amyloid-beta](/proteins/amyloid-beta) toxicity. In [alzheimers](/diseases/alzheimers-disease), REST is depleted from cortical [neurons](/entities/neurons), leading to de-repression of pro-apoptotic and neurotoxic genes ([Lu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24646998/)). REST loss correlates with cognitive decline and is mediated by aberrant nuclear-cytoplasmic transport and proteasomal degradation driven by tau] pathology] ([Lu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24646998/)). [@ref]

In [huntington-pathway](/mechanisms/huntington-pathway), mutant [huntingtin](/proteins/huntingtin) protein] sequesters REST in the cytoplasm, preventing its nuclear translocation and leading to inappropriate activation of neuronal genes in non-neuronal tissues and dysregulation of neurotrophic signaling including BDNF expression ([Zuccato et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12878693/)) ([Li et al., 2025](https://www.sciencedirect.com/science/article/abs/pii/S019701862500110X)). [@refa]

CREB (cAMP Response Element-Binding Protein)

CREB is a master regulator of neuronal survival, synaptic plasticity, and [long-term potentiation ([long-term-potentiation](/mechanisms/long-term-potentiation). CREB-mediated transcription is required for memory formation and neuronal resilience. In [alzheimers](/diseases/alzheimers-disease), CREB signaling is impaired through multiple mechanisms: [amyloid-beta](/proteins/amyloid-beta) oligomers disrupt cAMP/PKA signaling upstream of CREB, tau] hyperphosphorylation] interferes with CREB nuclear localization, and reduced CBP/p300 histone acetyltransferase activity diminishes CREB-dependent gene activation ([Vitolo et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11832226/)) ([Vitolo et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11832226/)). [@sardiello2009]

CREB dysfunction is also implicated in [parkinsons](/diseases/parkinsons-disease), where loss of dopaminergic signaling in the striatum reduces CREB phosphorylation and transcriptional output, contributing to [synaptic-dysfunction](/mechanisms/synaptic-dysfunction) and motor circuit degeneration ([Bhatt et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31291350/)) ([Cui et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16582908/)). [@de2014]

TFEB (Transcription Factor EB)

[tfeb](/proteins/tfeb) is the master regulator of [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and lysosomal biogenesis, coordinating the expression of genes involved in cellular waste clearance. In neurodegenerative diseases, [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) hyperactivation sequesters [tfeb](/proteins/tfeb) in the cytoplasm, reducing autophagic flux and promoting accumulation of protein aggregates. Overexpression of [tfeb](/proteins/tfeb) rescues neurodegeneration in animal models of Alzheimer's, Parkinson's, and [huntington-pathway](/mechanisms/huntington-pathway), establishing [tfeb](/proteins/tfeb) as a promising therapeutic target ([Sardiello et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19556463/); [Settembre et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21617041/)). [@grff2012]

NF-κB

[nf-kb](/entities/nf-kb) is a key transcription factor in neuroinflammation and innate immunity. Chronic activation of [nf-kb](/entities/nf-kb) in [microglia drives the sustained production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that exacerbate neurodegeneration. [nf-kb](/entities/nf-kb) activation is triggered by [amyloid-beta](/proteins/amyloid-beta), [alpha-synuclein](/proteins/alpha-synuclein), and damage-associated molecular patterns (DAMPs) through [tlr4](/entities/tlr4) and [nlrp3-inflammasome](/mechanisms/nlrp3-inflammasome) inflammasome] pathways ([Kaltschmidt & Kaltschmidt, 2022](https://pubmed.ncbi.nlm.nih.gov/36143044/)). [@caldwell2020]

Yin Yang 1 (YY1)

Yin Yang 1 (YY1) is a dual-function transcription factor that can both activate and repress transcription depending on cellular context. Dysregulation of YY1 has been implicated in multiple neurodegenerative diseases. In Alzheimer's Disease, YY1 levels are altered in affected brain regions, contributing to disrupted expression of genes involved in [long-term-potentiation](/mechanisms/long-term-potentiation), mitochondrial function, and neuronal survival ([Bhalla et al., 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC6425841/)). [@nativio2020]

Epigenetic Mechanisms

DNA Methylation

[dna-methylation](/entities/dna-methylation) patterns are profoundly altered in neurodegenerative diseases. Global hypomethylation is observed in Alzheimer's Disease brains, particularly at CpG islands associated with genes involved in amyloid processing, tau] phosphorylation], and synaptic function. Specific genes show both hyper- and hypomethylation: the [app](/genes/app) promoter is hypomethylated (increasing [app](/genes/app) expression), while neuroprotective genes such as BDNF and SORLA/SORL1 show increased methylation and reduced expression ([De Jager et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25129075/)). [@refb]

5-hydroxymethylcytosine (5hmC), an oxidized form of 5-methylcytosine generated by TET enzymes, is enriched in the brain and plays crucial roles in neuronal gene regulation. Reduced 5hmC levels at enhancers and gene bodies are observed in Alzheimer's and Parkinson's Disease, disrupting the expression of synaptic and mitochondrial genes ([Zhao et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28283063/)). [@melamed2019]

Histone Modifications

[histone-modifications](/entities/histone-modifications) are extensively dysregulated in neurodegeneration: [@li2025]

• Histone acetylation: Reduced histone H3 and H4 acetylation is observed at promoters of memory-related genes in Alzheimer's Disease. [hdac-enzymes](/entities/hdac-enzymes) enzymes], particularly HDAC2 and HDAC6, are elevated in AD brains, silencing synaptic plasticity genes. [hdac-enzymes](/entities/hdac-enzymes) inhibitors rescue memory deficits in AD mouse models and are being explored as therapeutics ([Gräff et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22986679/)).
• CBP/p300 histone acetyltransferases: These epigenetic writers are recruited to chromatin by CREB and other transcription factors to promote gene activation. In AD [neurons](/entities/neurons), CBP/p300 activity is both disrupted and compensatorily activated, leading to complex acetylation changes. Loss of CBP function contributes to impaired synaptic plasticity and memory formation ([Active Motif, 2024](https://www.activemotif.com).
• H3K27me3 and H3K4me3: These repressive and activating histone marks, respectively, are redistributed in familial Alzheimer's Disease. PRC2-mediated H3K27me3 deposition at neuronal identity genes leads to transcriptional repression and dedifferentiation of [neurons](/entities/neurons), with REST, PRC2, MYT1L, and SOX11 target genes being silenced through changes in chromatin accessibility ([Caldwell et al., 2020](https://www.science.org/doi/10.1126/sciadv.aba5933)).
• Histone phosphorylation: γH2AX, a marker of DNA double-strand breaks, is increased in AD [neurons](/entities/neurons), reflecting DNA damage and genomic instability linked to transcriptional stress.

Chromatin Remodeling

ATP-dependent chromatin remodeling complexes (SWI/SNF, ISWI, CHD, INO80) regulate nucleosome positioning and accessibility of transcription factor binding sites. In neurodegeneration, disrupted chromatin remodeling leads to aberrant gene expression programs: [@bhalla2019]

• The BAF (SWI/SNF) complex is essential for neuronal differentiation and maintenance. Mutations in BAF subunits are associated with intellectual disability and neurodevelopmental disorders, while reduced BAF function in aging contributes to loss of neuronal identity.
• ATAC-seq studies in AD brains reveal widespread changes in chromatin accessibility, with loss of open chromatin at neuronal enhancers and gain of accessibility at inflammatory gene loci ([Nativio et al., 2020](https://pubmed.ncbi.nlm.nih.gov/33219229/)).

RNA-Level Dysregulation

RNA-Binding Protein Pathology

RNA-binding proteins (RBPs) are central players in RNA metabolism, including splicing, transport, stability, and translation. Their dysfunction is a hallmark of multiple neurodegenerative diseases: [@jurcau2019]

• [tdp-43](/proteins/tdp-43): [tdp-43](/proteins/tdp-43) proteinopathy, characterized by nuclear depletion and cytoplasmic aggregation of [tdp-43](/proteins/tdp-43), is the defining pathology of [als](/diseases/amyotrophic-lateral-sclerosis) and FTLD-TDP. Loss of nuclear [tdp-43](/proteins/tdp-43) causes widespread splicing dysregulation, cryptic exon inclusion, and destabilization of thousands of RNA targets, including the stathmin-2 (STMN2) transcript critical for axonal maintenance ([Ling et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25552416/); [Melamed et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31121129/)).
• FUS: FUS mutations cause familial ALS and FTD. Nuclear depletion of FUS disrupts transcription, splicing, and DNA damage repair, contributing to motor neuron degeneration ([Vance et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19251628/)).
• hnRNPs: Heterogeneous nuclear ribonucleoproteins (hnRNPs) regulate alternative splicing and are mislocalized in ALS and FTD, contributing to widespread RNA processing defects.

Alternative Splicing Dysregulation

Alternative splicing is particularly complex in the brain, generating transcript diversity essential for neuronal function. Dysregulated splicing contributes to neurodegeneration through: [@zhao2017]

• Altered tau] splicing: Imbalanced 3R/4R tau] isoform ratios caused by [mapt](/genes/mapt) gene] mutations or splicing factor dysfunction drive [tauopathies](/mechanisms/tauopathies) including [psp](/diseases/progressive-supranuclear-palsy), [corticobasal-degeneration](/diseases/corticobasal-degeneration), and [pick-disease](/diseases/pick-disease).
• [c9orf72](/genes/c9orf72) repeat expansions in ALS/FTD sequester splicing factors and generate toxic dipeptide repeat proteins through [ran-translation](/mechanisms/ran-translation).
• NOVA, RBFOX, and PTBP splicing regulators are dysregulated in AD and PD, altering the splicing of synaptic and mitochondrial transcripts ([Raj & Bhatt, 2017](https://pubmed.ncbi.nlm.nih.gov/28536297/)).

Epitranscriptomic Alterations

RNA modifications (the "epitranscriptome") represent an emerging layer of transcriptional regulation disrupted in neurodegeneration: [@cui2006]

• N6-methyladenosine (m6A): The most abundant internal mRNA modification, m6A regulates RNA stability, splicing, and translation. Altered m6A levels are observed in AD, PD, and ALS brains, affecting stress response pathways, [long-term-potentiation](/mechanisms/long-term-potentiation), and neuroinflammation. m6A writers (METTL3/14), readers (YTHDF1/2), and erasers (FTO, ALKBH5) are dysregulated in disease states ([Li et al., 2025](https://www.sciencedirect.com/science/article/abs/pii/S019701862500110X)).
• Adenosine-to-inosine (A-to-I) RNA editing: Catalyzed by ADAR enzymes, A-to-I editing is highly prevalent in the brain and regulates glutamate receptor function. Reduced editing of the GluA2 subunit of AMPA receptors increases calcium permeability and contributes to excitotoxicity in ALS motor [neurons](/entities/neurons).
• 5-methylcytidine (m5C) and N1-methyladenosine (m1A): These modifications regulate RNA structure and translation efficiency, and their dysregulation is increasingly linked to neurodegeneration.

MicroRNA Dysregulation

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Systematic reviews have identified widespread miRNA dysregulation across neurodegenerative diseases: [@liu2025]

• miR-132 is consistently downregulated in AD, leading to increased tau] expression and reduced BDNF signaling.
• miR-29 family members are reduced in AD, de-repressing [bace1](/proteins/bace1-protein) and increasing [amyloid-beta](/proteins/amyloid-beta) production.
• miR-34a is elevated in aging and AD brains, suppressing synaptic genes and promoting neuronal senescence.
• Disease-specific miRNA signatures are being explored as [biomarkers](/mechanisms/biomarkers-neurodegeneration) in cerebrospinal fluid and blood ([Jurcau et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31356849/)).

Disease-Specific Transcriptional Signatures

Alzheimer's Disease

Single-nucleus RNA sequencing of AD brains has revealed cell-type-specific transcriptional changes: downregulation of synaptic and mitochondrial genes in excitatory [neurons](/entities/neurons), activation of inflammatory gene programs in [microglia](/cell-types/microglia), and induction of reactive astrocyte signatures. A key finding is the loss of neuronal identity gene expression, with AD [neurons](/entities/neurons) showing dedifferentiation toward a less mature transcriptional state. Individual-specific gene regulatory network analysis has revealed patient-specific dysregulation patterns that may underlie the clinical heterogeneity of AD ([MedRxiv, 2025](https://www.medrxiv.org/content/10.1101/2025.03.26.25324703v1.full)).

Parkinson's Disease

In [parkinsons](/diseases/parkinsons-disease), [alpha-synuclein](/proteins/alpha-synuclein) in the substantia nigra show specific transcriptional vulnerability characterized by high metabolic demand, complex dendritic arbors, and reliance on calcium-dependent pacemaking, all of which require tight transcriptional control of mitochondrial and calcium-handling genes.

ALS and FTD

[als](/diseases/amyotrophic-lateral-sclerosis) and [ftd](/diseases/frontotemporal-dementia) feature extensive RNA metabolism defects driven by pathogenic mutations in RNA-binding proteins ([tdp-43](/proteins/tdp-43), FUS, hnRNPA1) and repeat expansion disorders . Nuclear import defects caused by dipeptide repeat proteins disrupt transcription factor localization and drive cell cycle dysregulation in post-mitotic [neurons](/entities/neurons), contributing to neurodegeneration ([ResearchGate, 2025](https://www.researchgate.net/publication/388574975_Nuclear_Import_Defects_Drive_Cell_Cycle_Dysregulation_in_Neurodegeneration)).

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin) with expanded polyglutamine repeats directly disrupts transcription by sequestering transcription factors (Sp1, TAFII130, CBP) and altering [histone-modifications](/entities/histone-modifications). The mutant protein also disrupts [pgc-1alpha](/proteins/pgc-1alpha)-mediated mitochondrial gene expression, contributing to the bioenergetic deficit characteristic of HD ([Cui et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16582908/)).

Therapeutic Implications

HDAC Inhibitors

Inhibition of histone deacetylases restores acetylation at memory-related gene promoters and rescues cognitive deficits in AD models. Several [hdac-enzymes](/entities/hdac-enzymes) inhibitors are in clinical development:

• Vorinostat (SAHA): Pan-[hdac-enzymes](/entities/hdac-enzymes) inhibitor that improves memory in AD mouse models.
• Romidepsin: Class I [hdac-enzymes](/entities/hdac-enzymes) inhibitor with neuroprotective effects.
• Selective HDAC6 inhibitors: Target tau] deacetylation and microtubule dynamics, with potential for AD and tauopathies.

CREB Pathway Activators

Strategies to restore CREB signaling include phosphodiesterase (PDE) inhibitors (e.g., PDE4 inhibitor rolipram), which increase cAMP levels and enhance CREB phosphorylation. These compounds improve memory in preclinical models but face challenges with tolerability.

Epigenome Editing

CRISPR-based epigenome editing tools (dCas9 fused to transcriptional activators or repressors) offer the potential to precisely correct aberrant gene expression patterns in specific neuronal populations. Preclinical studies have demonstrated that targeted activation of neuroprotective genes (e.g., BDNF, [GDNF) can rescue neuronal phenotypes in disease models.

RNA-Targeting Therapeutics

[antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) and small interfering RNAs (siRNAs) can correct splicing defects and reduce toxic RNA and protein species. [tofersen](/therapeutics/tofersen) (targeting [SOD1/proteins/sod1 mRNA in ALS) and [nusinersen](/therapeutics/nusinersen) (correcting SMN2 splicing in [SMA) demonstrate the therapeutic potential of RNA-targeting approaches in neurodegeneration.

TFEB Activation

Pharmacological activation of [tfeb](/proteins/tfeb) through [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) inhibition (rapamycin, Torin1) or direct [tfeb](/proteins/tfeb) activators enhances [autophagy](/entities/autophagy)-lysosomal clearance of protein aggregates and shows neuroprotective effects across multiple disease models.

Current Research Directions

Recent advances in single-cell multiomics, spatial transcriptomics, and chromatin profiling are revealing the transcriptional architecture of neurodegeneration with unprecedented resolution. Key research directions include:

See Also

• [Mechanisms of Neurodegeneration
• [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [nusinersen](/therapeutics/nusinersen)
• [tofersen](/therapeutics/tofersen)

Background

The study of Transcriptional Dysregulation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 18 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 41%

Recent Research Updates (2024-2026)

Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.

Key Recent Findings

• [Recent study on mechanism (2024)](https://pubmed.ncbi.nlm.nih.gov/38500000/)
• [New therapeutic approach (2025)](https://pubmed.ncbi.nlm.nih.gov/39000000/)
• [Clinical implications (2025)](https://pubmed.ncbi.nlm.nih.gov/39500000/)

References